Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.
Loading...
Embargo End Date
ICR Authors
Authors
Saint-Ghislain, M
Chabaud, S
Dalenc, F
Allouache, D
Cameron, D
Martinez, M
Grenier, J
Barthelemy, P
Brunt, M
Kaluzinski, L
Mailliez, A
Legouffe, E
Hardy-Bessard, A-C
Giacchetti, S
Mouret-Reynier, M-A
Canon, J-L
Bliss, J
Lemonnier, J
Andre, F
Bachelot, T
Cottu, P
Chabaud, S
Dalenc, F
Allouache, D
Cameron, D
Martinez, M
Grenier, J
Barthelemy, P
Brunt, M
Kaluzinski, L
Mailliez, A
Legouffe, E
Hardy-Bessard, A-C
Giacchetti, S
Mouret-Reynier, M-A
Canon, J-L
Bliss, J
Lemonnier, J
Andre, F
Bachelot, T
Cottu, P
Document Type
Journal Article
Date
2025-05-01
Date Accepted
2025-03-17
Abstract
BACKGROUND: The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses. PATIENTS AND METHODS: We randomly assigned 1278 patients in a 1 : 1 ratio to receive 2 years of placebo or everolimus, added to endocrine therapy for up to 4 years after initiation. Randomization was stratified by endocrine therapy agent, prior adjuvant versus neoadjuvant therapy, progesterone receptor expression, and lymph node involvement. Subgroup analyses by each stratification factor were pre-specified. Post hoc analyses were carried out according to menopausal status and age. Treatment adherence was also analyzed. RESULTS: We observed a limited trend toward more favorable prognostic features in tamoxifen-treated patients, with more frequent estrogen receptor-positive/progesterone receptor-positive tumors (88.5% versus 84.1%, P = 0.026) and less frequent pN2-positive status (39.8% versus 46.0%, P = 0.032). In premenopausal women, we observed a numerical benefit of everolimus: 3-year disease-free survival was 86% in the placebo group and 90% in the everolimus group (hazard ratio 0.76, 95% confidence interval 0.43-1.34). In premenopausal patients treated with tamoxifen (n = 153; 12.3%), we observed an even stronger trend in favor of everolimus as 3-year DFS was 84% in the placebo group and 91% in the everolimus group (hazard ratio 0.54, 95% confidence interval 0.28-1.02). Early discontinuation of either everolimus or placebo was less frequent in the tamoxifen group than in the aromatase inhibitor group: 48.0% versus 56.9% (P = 0.028). CONCLUSIONS: The present post hoc analyses generate hypotheses regarding the interaction between menopausal status, tamoxifen, and everolimus in patients with high-risk, ER-positive, human epidermal growth factor receptor type 2-negative early breast cancer. They suggest that tamoxifen alone is an underpowered endocrine treatment in high-risk premenopausal patients.
Citation
ESMO Open, 2025, 10 (5), pp. 105050 -
Source Title
ESMO Open
Publisher
ELSEVIER
ISSN
2059-7029
eISSN
2059-7029
Collections
Research Team
Clin Trials & Stats Unit